Turkish Competition Authority fined Novartis TL 165,464,716.48 and Roche TL 112,972,552.65 following an investigation to decide whether they had infringed Article 4 of the Competition Act No.4054 prohibiting anti-competitive agreements with the purpose to ensure common use of more expensive Lucentis rather than Altuzan used for the treatment of eye diseases. The press release dated 22.01.2021 regarding the decision of Turkish Competition Board, dated 21.01.2021 and numbered 21-04/52-21, is available via https://www.rekabet.gov.tr/tr/Guncel/novartis-saglik-gida-ve-tarim-urunleri-s-b511f260945ceb11812800505694b4c6